Jaan Biotherapeutics LLC (JBT) is a biotechnology company developing a first-in-class regenerative therapy that modulates the activity of microRNAs to repair damaged heart muscle to treat Ischemic Heart Disease, the largest cause of death in the US. MicroRNAs (miRs) function in RNA silencing and post-transcriptional regulation of gene expression by modulating the activity of a number of genes and compensatory pathways. JBT has designed, developed and patented a single virus, known as JBT-miR2 that delivers inhibitors to four miRs; miR-100, miR-99, let-7a and let-7c to reprogram adult mono-nuclear de-differentiated cardiomyocytes within the murine ischemic heart to proliferate. JBT-miR2 has completed extensive preclinical safety and efficacy testing in mice models of the disease. The results of these studies show a 45% decrease in scar tissue, 30% decrease in cardiac volumes and 20% increase in heart function with no safety concerns. We are seeking funds to complete our IND studies.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):